Divergence and convergence of commercial and scientific priorities in drug development: The case of Zelmid, the first SSRI antidepressant
Shai Mulinari
Social Science & Medicine2015
Summary (paraphrased)
Drawing on interviews with industry and academic scientists involved in the Zelmid project plus textual sources, the paper reconstructs the development of the first SSRI to reach the market. Zelmid (zimelidine) was synthesized in 1971, launched by the Swedish firm Astra in 1982, and withdrawn the following year because of adverse neurological effects. The author uses the case to show how commercial and scientific priorities converged and diverged across the experimental, preclinical, and clinical phases of a mechanism-based ("rational") drug-discovery program.
Why it’s in the corpus
foundational precedent for SSRI-class severe post-marketing harms and withdrawal
Why it’s in the systems review
The corpus's PSSD-recognition arc (EMA 2019, FDA labeling, class-wide signal reviews) needs its historical bookend: the SSRI class has already had a member pulled from the market for severe post-marketing harms. A peer-reviewed history of Zelmid's rise and fall supplies exactly that precedent and documents how early post-marketing neurological toxicity was handled by the manufacturer and regulators, giving readers a baseline for judging whether PSSD recognition has been proportionate. It also anchors the androgen-clearance axis: Zelmid's Astra/Carlsson lineage is the same pharmacological era Powers discusses.
Related records
- Peer-reviewed paper
Guillain-Barre syndrome following zimeldine treatment
Jan Fagius; Per Olof Osterman; Åke Sidén; B.-E. Wiholm · Journal of Neurology, Neurosurgery & Psychiatry
The authors review thirteen cases of Guillain-Barré syndrome, all with a similar temporal relationship to recent commencement of the antidepressant zimelidine. They estimate the risk of developing the syndrome was increased about 25-fold among patients…
MECH-0461985PSSDSystems review · Oct 2026